glutamate ionotropic receptor NMDA type subunit 2A
Last updated 11 Apr 2023
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The GRIN2A gene provides instructions for making a protein called GluN2A (formerly known as NR2A). This protein is found in nerve cells (neurons) in the brain and spinal cord, including regions of the brain involved in speech and language.
Video picks for GenesVideo library
Normal function
The GRIN2A gene provides instructions for making a protein called GluN2A (formerly known as NR2A). This protein is found in nerve cells (neurons) in the brain and spinal cord, including regions of the brain involved in speech and language.
The GluN2A protein is one component (subunit) of a subset of NMDA receptors. There are several types of NMDA receptors, made up of different combinations of protein components. NMDA receptors are glutamate-gated ion channels; when brain chemicals called glutamate and glycine attach to the receptor, a channel opens, allowing positively charged particles (cations) to flow through. The flow of cations generates currents that activate (excite) neurons to send signals in the brain. NMDA receptors are involved in normal brain development, changes in the brain in response to experience (synaptic plasticity), learning, and memory. They also appear to play a role during deep (slow-wave) sleep.
The GluN2A subunit of NMDA receptors determines where in the brain the receptor is located and how it functions. It also provides the site to which glutamate binds.
Conditions referring to this gene or chromosome
Other names
EPND
GluN2A
glutamate receptor ionotropic, NMDA 2A isoform 1 precursor
glutamate receptor ionotropic, NMDA 2A isoform 2 precursor
glutamate receptor, ionotropic, N-methyl D-aspartate 2A
LKS
N-methyl D-aspartate receptor subtype 2A
N-methyl-D-aspartate receptor channel, subunit epsilon-1
N-methyl-D-aspartate receptor subunit 2A
NMDAR2A
NR2A
Patient picks for Genes

Diabetes
Changes in type 2 diabetes care - what it means for you
If you are living with type 2 diabetes your treatment may soon change to be tailored around you and your specific needs - which will help improve your long-term health. Read on to find out what the changes are and what they mean for you.
by Lawrence Higgins

Diabetes
Type 2 diabetes treatment
Although diabetes cannot be cured, it can be treated successfully. If a high blood sugar level is brought down to a normal level, your symptoms will ease and your risk of long-term complications will be much lower.
by Dr Doug McKechnie, MRCGP

Tests and investigations
Blood groups and types
ABO and rhesus are both types of antigens found on the surface of red blood cells. There are lots of other types but these are the most important.
by Dr Rosalyn Adleman, MRCGP

Diabetes
MHRA approves teplizumab to delay progression of type 1 diabetes
Teplizumab (Tzield) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to help delay the onset of Stage 3 type 1 diabetes (T1D). Read on to see what this means if you are prescribed teplizumab and what it does for you.
by Lawrence Higgins

Diabetes
Video: How do you know if you have type 2 diabetes?
There are a lot of symptoms involved with type 2 diabetes, some of which may be mistaken for something else. Our experts look at what you need to look out for, and answer some other common questions about this widespread condition.
by Dr Partha Kar, FRCP

Diabetes
Type 2 diabetes
Type 2 diabetes can occur at any age, including during childhood, but it occurs mainly in people aged over 40. The first-line treatment is diet, weight control and physical activity. The good news is that many people can stay well using these lifestyle measures. However if the blood sugar (glucose) level remains high then tablets to reduce the blood glucose level are usually advised. Insulin injections are needed in some cases. Other treatments include reducing blood pressure if it is high, lowering high cholesterol levels, and also other measures to reduce the risk of complications.
by Dr Colin Tidy, MRCGP
Related patient information and medicines

Patient information leaflet
Mastocytosis and mast cell disorders
A mast cell is a type of white blood cell. There are several forms of mastocytosis. I... These include: Physical triggers - for example, heat, cold, rubbing, sunlight, tiredness, lots of exercise, a high temperature (fever). Emotional triggers - for example, stress. Some foods - for example, cheese, spices, shellfish, food preservatives,.

Patient information leaflet
Motor neurone disease
Motor neurone disease (MND) is a neurological condition causes a progressive weakness and wasting of many of the muscles in the body. This leaflet is mainly about amyotrophic lateral sclerosis (ALS), which is the most common type of motor neurone disease. It can slow down the disease ... Riluzole works by its effect on glutamate - a chemical which.

Patient information leaflet
Type 2 diabetes treatment
If a high blood sugar level is brought down to a normal level, your symptoms will ease and your risk of long-term complications will be much lower. Managing type 2 diabetes Keeping your blood sugar (glucose) well controlled is key to reducing your risk of long-term complications such as heart, kidney or eye problems. Regardless of whether you need.

Patient information leaflet
Diabetes and illness
It is very important to know how to cope with illness if you have diabetes or know or care for somebody with diabetes. The increased glucose level can make you become very lacking in fluid in the bod... Sick day diabetes guidelines The following guidance is provided by Diabetes UK: Contact your general practice or diabetes team who will help you.

Patient information leaflet
Myasthenia gravis
People with myasthenia gravis have a ... The muscles become easily tired and weak. What causes myasthenia gravis. Myasthenia gravis is an autoimmune disease. This means that the immune system The immune system (which normally protects the body from infections) mistakenly attacks itself. (Other autoimmune diseases include type 1 diabetes Type 1.

Patient information leaflet
Blood groups and types
ABO and rhesus are both types of antigens found on the surface of red blood cells. There are lots of other types but these are the most important. The main reasons to know your blood group are if you need to have a blood transfusion or if you are pregnant. What is a blood group. Red blood cells (erythrocytes) have certain proteins on their.
Further reading and references
- glutamate ionotropic receptor NMDA type subunit 2A; MedlinePlus, National Library of Medicine.
- Burnashev N, Szepetowski P. NMDA receptor subunit mutations in neurodevelopmental disorders. Curr Opin Pharmacol. 2015 Feb;20:73-82. doi: 10.1016/j.coph.2014.11.008. Epub 2014 Dec 11.
- Carvill GL, Regan BM, Yendle SC, O'Roak BJ, Lozovaya N, Bruneau N, Burnashev N, Khan A, Cook J, Geraghty E, Sadleir LG, Turner SJ, Tsai MH, Webster R, Ouvrier R, Damiano JA, Berkovic SF, Shendure J, Hildebrand MS, Szepetowski P, Scheffer IE, Mefford HC. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet. 2013 Sep;45(9):1073-6. doi: 10.1038/ng.2727. Epub 2013 Aug 11.
- Lemke JR, Lal D, Reinthaler EM, Steiner I, Nothnagel M, Alber M, Geider K, Laube B, Schwake M, Finsterwalder K, Franke A, Schilhabel M, Jahn JA, Muhle H, Boor R, Van Paesschen W, Caraballo R, Fejerman N, Weckhuysen S, De Jonghe P, Larsen J, Moller RS, Hjalgrim H, Addis L, Tang S, Hughes E, Pal DK, Veri K, Vaher U, Talvik T, Dimova P, Guerrero Lopez R, Serratosa JM, Linnankivi T, Lehesjoki AE, Ruf S, Wolff M, Buerki S, Wohlrab G, Kroell J, Datta AN, Fiedler B, Kurlemann G, Kluger G, Hahn A, Haberlandt DE, Kutzer C, Sperner J, Becker F, Weber YG, Feucht M, Steinbock H, Neophythou B, Ronen GM, Gruber-Sedlmayr U, Geldner J, Harvey RJ, Hoffmann P, Herms S, Altmuller J, Toliat MR, Thiele H, Nurnberg P, Wilhelm C, Stephani U, Helbig I, Lerche H, Zimprich F, Neubauer BA, Biskup S, von Spiczak S. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet. 2013 Sep;45(9):1067-72. doi: 10.1038/ng.2728. Epub 2013 Aug 11.
- Lesca G, Rudolf G, Bruneau N, Lozovaya N, Labalme A, Boutry-Kryza N, Salmi M, Tsintsadze T, Addis L, Motte J, Wright S, Tsintsadze V, Michel A, Doummar D, Lascelles K, Strug L, Waters P, de Bellescize J, Vrielynck P, de Saint Martin A, Ville D, Ryvlin P, Arzimanoglou A, Hirsch E, Vincent A, Pal D, Burnashev N, Sanlaville D, Szepetowski P. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet. 2013 Sep;45(9):1061-6. doi: 10.1038/ng.2726. Epub 2013 Aug 11.
- Paoletti P. Molecular basis of NMDA receptor functional diversity. Eur J Neurosci. 2011 Apr;33(8):1351-65. doi: 10.1111/j.1460-9568.2011.07628.x. Epub 2011 Mar 14.
- Reutlinger C, Helbig I, Gawelczyk B, Subero JI, Tonnies H, Muhle H, Finsterwalder K, Vermeer S, Pfundt R, Sperner J, Stefanova I, Gillessen-Kaesbach G, von Spiczak S, van Baalen A, Boor R, Siebert R, Stephani U, Caliebe A. Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region. Epilepsia. 2010 Sep;51(9):1870-3. doi: 10.1111/j.1528-1167.2010.02555.x.
- Turner SJ, Mayes AK, Verhoeven A, Mandelstam SA, Morgan AT, Scheffer IE. GRIN2A: an aptly named gene for speech dysfunction. Neurology. 2015 Feb 10;84(6):586-93. doi: 10.1212/WNL.0000000000001228. Epub 2015 Jan 16.
- Wyllie DJ, Livesey MR, Hardingham GE. Influence of GluN2 subunit identity on NMDA receptor function. Neuropharmacology. 2013 Nov;74:4-17. doi: 10.1016/j.neuropharm.2013.01.016. Epub 2013 Jan 31.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

